UPDATE: PredicineCARE™ Liquid Biopsy Assay Featured in NEJM for patient enrollment in Phase III

The trial targets patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer (mBC). “The …

Continue

Do you trust this headline?

Based on recent headline ratings, 86% of this readership currently trusts the local media, which has an average score of 82% regionally and is currently trending positive.

86%

Media Trust Score86%

Read All

In

News